Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsNew phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing
Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.
Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D
Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis
1.
Study reveals link between new-onset type 2 diabetes and some obesity-related cancers
2.
Researchers find distinct cell receptors with the potential for new treatments.
3.
Preoperative Embolization Linked to Relapse-Free Survival in Meningioma
4.
Second opinions don't significantly delay breast cancer treatment
5.
Year in Review: Chronic Lymphocytic Leukemia
1.
How Prevident is Revolutionizing Oral Care
2.
The Capmist DM: A Revolutionary Way to Combat Dry Mouth
3.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
4.
Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells
5.
Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
2.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge